Magnesium physiology and pathogenic mechanisms that contribute to the development of the metabolic syndrome

Magnesium Research

Volumn 20, Issue 2, 2007, Pages 107-129

  Belin, Rashad J ^a,c   He, Ka ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b IL   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Insulin resistance; Magnesium; Metabolic syndrome

Indexed keywords

MAGNESIUM;

ANIMAL; CARDIOVASCULAR DISEASE; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; INSULIN RESISTANCE; MAGNESIUM; METABOLIC SYNDROME X;

EID: 34447506688     PISSN: 09531424     EISSN: None     Source Type: Journal    
DOI: 10.1684/mrh.2007.0096     Document Type: Review

References (325)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-28.
2. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 2004; 33: 351-75; [table of contents].
3. Reynolds K, He J. Epidemiology of the metabolic syndrome. Am J Med Sci 2005; 330: 273-9.
4. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-9.
5. Reisin E, Alpert MA. Definition of the metabolic syndrome: current proposals and controversies. Am J Med Sci 2005; 330: 269-72.
6. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 2005; 12: 295-300.
7. Hanefeld M, Leonhardt W. Das Metabolische Syndrom. Dl Gesundh Wesen 1981; 36: 545-51.
8. Alberti KG. Impaired glucose tolerance: what are the clinical implications? Diabetes Res Clin Pract 1998; 40(Suppl): S3-S8.
9. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study oflnsulin Resistance (EGIR). Diabet Med 1999; 16: 442-3.
10. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
11. Grundy SM, Hansen B, Smith Jr. SC, Cleeman JI, Kalin RA. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004; 109: 551-6.
12. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-80.
13. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149: 1514-20.
14. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
15. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-94.
16. Bonora E, Targher G, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, Saggiani F, Poli M, Perbellini S, Raffaelli A, Gemma L, Santi L, Bonadonna RC, Muggeo M. The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med 2004; 21: 52-8.
17. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004; 140: 167-74.
18. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-9.
19. Rutter MK, Meigs JB, Sullivan LM, D'Agostino Sr. RB, Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004; 110: 380-5.
20. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004; 164: 1066-76.
21. Cowey S, Hardy RW. The metabolic syndrome: A high-risk state for cancer? Am J Pathol 2006; 169: 1505-22.
22. Mule G, Cottone S, Nardi E, Andronico G, Cerasola G. Metabolic syndrome in subjects with essential hypertension: relationships with subclinical cardiovascular and renal damage. Minerva Cardioangiol 2006; 54: 173-94.
23. Vgontzas AN, Bixler EO, Chrousos GP. Sleep apnea is a manifestation of the metabolic syndrome. Sleep Med Rev 2005; 9: 211-24.
24. Neuschwander-Tetri BA. Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci 2005; 330: 326-35.
25. Pasquali R, Gambineri A. Polycystic ovary syndrome: a multifaceted disease from adolescence to adult age. Ann N Y Acad Sci 2006; 1092: 158-74.
26. McKeown NM, Meigs JB, Liu S, Saltzman E, Wilson PW, Jacques PF. Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort. Diabetes Care 2004; 27: 538-46.
27. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003; 163: 427-36.
28. Carnethon MR, Loria CM, Hill JO, Sidney S, Savage PJ, Liu K. Risk factors for the metabolic syndrome: the Coronary Artery Risk Development in Young Adults (CARDIA) study, 1985-2001. Diabetes Care 2004; 27: 2707-15.
29. Laaksonen DE, Lakka HM, Salonen JT, Niskanen LK, Rauramaa R, Lakka TA. Low levels of leisure-time physical activity and cardiorespiratory fitness predict development of the metabolic syndrome. Diabetes Care 2002; 25: 1612-8.
30. Ford ES. Prevalence of the metabolic syndrome in US populations. Endocrinol Metab Clin North Am 2004; 33: 333-50.
31. Mills GW, Avery PJ, McCarthy MI, Hattersley AT, Levy JC, Hitman GA, Sampson M, Walker M. Heritability estimates for beta cell function and features of the insulin resistance syndrome in UK families with an increased susceptibility to type 2 diabetes. Diabetologia 2004; 47: 732-8.
32. Phillips C, Lopez-Miranda J, Perez-Jimenez F, McManus R, Roche HM. Genetic and nutrient determinants of the metabolic syndrome. Curr Opin Cardiol 2006; 21: 185-93.
33. Semple RK, Chatterjee VK, O'Rahilly S. PPAR gamma and human metabolic disease. J Clin Invest 2006; 116: 581-9.
34. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES. The common PPARgamma Pro12A1a polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000; 26: 76-80.
35. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx JA. Pro12A1a substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20: 284-7.
36. Luan J, Browne PO, Harding AH, Halsall DJ, O'Rahilly S, Chatterjee VK, Wareham NJ. Evidence for gene-nutrient interaction at the PPARgamma locus. Diabetes 2001; 50: 686-9.
37. Wilson FH, Hariri A, Farhi A, Zhao H, Petersen KF, Toka HR, Nelson-Williams C, Raja KM, Kashgarian M, Shulman GI, Scheinman SJ, Lifton RP. A cluster of metabolic defects caused by mutation in a mitochondrial tRNA. Science 2004; 306: 1190-4.
38. Sullivan VK. Prevention and treatment of the metabolic syndrome with lifestyle intervention: where do we start?, J Am Diet Assoc 2006; 106: 668-71.
39. Esmaillzadeh A, Kimiagar M, Mehrabi Y, Azadbakht L, Hu FB, Willett WC. Fruit and vegetable intakes, C-reactive protein, and the metabolic syndrome. Am J Clin Nutr 2006; 84: 1489-97.
40. Millen BE, Pencina MJ, Kimokoti RW, Zhu L, Meigs JB, Ordovas JM, D'Agostino RB. Nutritional risk and the metabolic syndrome in women: opportunities for preventive intervention from the Framingham Nutrition Study. Am J Clin Nutr 2006; 84: 434-41.
41. Azadbakht L, Mirmiran P, Esmaillzadeh A, Azizi T, Azizi F. Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome. Diabetes Care 2005; 28: 2823-31.
42. Mazur A, Maier JA, Rock E, Gueux E, Nowacki W, Rayssiguier Y. Magnesium and the inflammatory response: potential physiopathological implications. Arch Biochem Biophys 2007; 458: 48-56.
43. Rayssiguier Y, Gueux E, Nowacki W, Rock E, Mazur A. High fructose consumption combined with low dietary magnesium intake may increase the incidence of the metabolic syndrome by inducing inflammation. Magnes Res 2006; 19: 237-43.
44. Rayssiguier Y, Mazur A. Clin Calcium 2005; 15: 245-8; [Magnesium and inflammation: lessons from animal models].
45. Rayssiguier Y, Gueux E, Weiser D. Effect of magnesium deficiency on lipid metabolism in rats fed a high carbohydrate diet. J Nutr 1981; 111: 1876-83.
46. Busserolles J, Gueux E, Rock E, Mazur A, Rayssiguier Y. High fructose feeding of magnesium deficient rats is associated with increased plasma triglyceride concentration and increased oxidative stress. Magnes Res 2003; 16: 7-12.
47. Guerrero-Romero F, Rodriguez-Moran M. Low serum magnesium levels and metabolic syndrome. Acta Diabetol 2002; 39: 209-13.
48. Song Y, Ridker PM, Manson JE, Cook NR, During JE, Liu S. Magnesium intake, C-reactive protein, and the prevalence of metabolic syndrome in middle-aged and older U.S. women. Diabetes Care 2005; 28: 1438-44.
49. Bo S, Durazzo M, Guidi S, Carello M, Sacerdote C, Silli B, Rosato R, Cassader M, Gentile L, Pagano G. Dietary magnesium and fiber intakes and inflammatory and metabolic indicators in middle-aged subjects from a population-based cohort. Am J Clin Nutr 2006; 84: 1062-9.
50. Corica F, Corsonello A, Ientile R, Cucinotta D, Di Benedetto A, Perticone F, Dominguez LJ, Barbagallo M. Serum ionized magnesium levels in relation to metabolic syndrome in type 2 diabetic patients. J Am Coll Nutr 2006; 25: 210-5.
51. He K, Liu K, Daviglus ML, Morris SJ, Loria CM, Van Horn L, Jacobs Jr. DR, Savage PJ. Magnesium intake and incidence of metabolic syndrome among young adults. Circulation 2006; 113: 1675-82.
52. Touyz RM. Magnesium in clinical medicine. Front Biosci 2004; 9: 1278-93.
53. Saris NE, Mervaala E, Karppanen H, Khawaja JA, Lewenstam A. Magnesium. An update on physiological, clinical and analytical aspects. Clin Chim Acta 2000; 294: 1-26.
54. Zhang A, Cheng TP, Altura BM. Magnesium regulates intracellular free ionized calcium concentration and cell geometry in vascular smooth muscle cells. Biochim Biophys Acta 1992; 1134: 25-9.
55. Chakraborti S, Chakraborti T, Mandal M, Mandal A, Das S, Ghosh S. Protective role of magnesium in cardiovascular diseases: a review. Mol Cell Biochem 2002; 238: 163-79.
56. Wang M, Tashiro M, Berlin JR. Regulation of L-type calcium current by intracellular magnesium in rat cardiac myocytes. J Physiol 2004; 555: 383-96.
57. Kawano S. Dual mechanisms of Mg2+ block of ryanodine receptor Ca2+ release channel from cardiac sarcoplasmic reticulum. Receptors Channels 1998; 5: 405-16.
58. Koss KL, Grubbs RD. Elevated extracellular Mg2+ increases Mg2+ buffering through a Ca-dependent mechanism in cardiomyocytes. Am J Physiol 1994; 267: C633-C641.
59. Gunther T. Mechanisms, regulation and pathologic significance of Mg2+ efflux from erythrocytes. Magnes Res 2006; 19: 190-8.
60. Reinhart RA. Magnesium metabolism. A review with special reference to the relationship between intracellular content and serum levels. Arch Intern Med 1988; 148: 2415-20.
61. Chubanov V, Gudermann T, Schlingmann KP. Essential role for TRPM6 in epithelial magnesium transport and body magnesium homeostasis. Pflugers Arch 2005; 451: 228-34.
62. Elin RJ, Hosseini JM, Gill Jr. JR. Erythrocyte and mononuclear blood cell magnesium concentrations are normal in hypomagnesemic patients with chronic renal magnesium wasting. J Am Coll Nutr 1994; 13: 463-6.
63. Quamme GA, de Rouffignac C. Epithelial magnesium transport and regulation by the kidney. Front Biosci 2000; 5: D694-D711.
64. Simon DB, Lu Y, Choate KA, Velazquez H, Al-Sabban E, Praga M, Casari G, Bettinelli A, Colussi G, Rodriguez-Soriano J, McCredie D, Milford D, Sanjad S, Lifton RP. Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption. Science 1999; 285: 103-6.
65. Schmitz C, Deason F, Perraud A. Molecular components of vertebrate magnesium homeostasis regulation. Magnes Res 2007; 20: 6-18.
66. Ryan MP, Devane J, Ryan MF, Counihan TB. Effects of diuretics on the renal handling of magnesium. Drugs 1984; 28(Suppl 1): 167-81.
67. Lostroh AJ, Krahl ME. Insulin action. Accumulation in vitro of Mg 2 + and K + in rat uterus: ion pump activity. Biochim Biophys Acta 1973; 291: 260-8.
68. Hwang DL, Yen CF, Nadler JL. Insulin increases intracellular magnesium transport in human platelets. J Clin Endocrinol Metab 1993; 76: 549-53.
69. Paolisso G, Sgambato S, Passariello N, Giugliano D, Scheen A, D'Onofrio F, Lefebvre PJ. Insulin induces opposite changes in plasma and erythrocyte magnesium concentrations in normal man. Diabetologia 1986; 29: 644-7.
70. Romani A, Marfella C, Scarpa A. Regulation of Mg2+ uptake in isolated rat myocytes and hepatocytes by protein kinase C. FEBS Lett 1992; 296: 135-40.
71. Corica F, Allegra A, Ientile R, Buemi M, Corsonello A, Bonanzinga S, Macaione S, Ceruso D. Changes in plasma, erythrocyte, and platelet magnesium levels in normotensive and hypertensive obese subjects during oral glucose tolerance test. Am J Hypertens 1999; 12: 128-36.
72. Touyz RM, Schiffrin EL. Angiotensin II and vasopressin modulate intracellular free magnesium in vascular smooth muscle cells through Na+-dependent protein kinase C pathways. J Biol Chem 1996; 271: 24353-8.
73. Ebel H, Gunther T. Na+/Mg2+ antiport in erythrocytes of spontaneously hypertensive rats: role of Mg2+ in the pathogenesis of hypertension. Magnes Res 2005; 18: 175-85.
74. Touyz RM, Yao G. Modulation of vascular smooth muscle cell growth by magnesium-role of mitogen activated protein kinases. J Cell Physiol 2003; 197: 326-35.
75. Laires MJ, Monteiro CP, Bicho M. Role of cellular magnesium in health and human disease. Front Biosci 2004; 9: 262-76.
76. Altura BM, Altura BT. Magnesium and cardiovascular biology: an important link between cardiovascular risk factors and atherogenesis. Cell Mol Biol Res 1995; 41: 347-59.
77. Amighi J, Sabeti S, Schlager O, Mlekusch W, Exner M. Lalouschek W, Ahmadi R, Minar E, Schillinger M. Low serum magnesium predicts neurological events in patients with advanced atherosclerosis. Stroke 2004; 35: 22-7.
78. Ascherio A, Rimm EB, Hernan MA, Giovannucci EL, Kawachi I, Stampfer MJ, Willett WC. Intake of potassium, magnesium, calcium, and fiber and risk of stroke among US men. Circulation 1998; 98: 1198-204.
79. Chang C, Varghese PJ, Downey J, Bloom S. Magnesium deficiency and myocardial infarct size in the dog. J Am Coll Cardiol 1985; 5: 280-9.
80. de Valk HW. Magnesium in diabetes mellitus. Neth J Med 1999; 54: 139-46.
81. Gomez MN. Magnesium and cardiovascular disease. Anesthesiology 1998; 89: 222-40.
82. Guerrero-Romero F, Rodriguez-Moran M. Hypomagnesemia, oxidative stress, inflammation, and metabolic syndrome. Diabetes Metab Res Rev 2006; 22: 471-6.
83. Neri LC, Johansen HL, Hewitt D, Marier J, Langner N. Magnesium and certain other elements and cardiovascular disease. Sci Total Environ 1985; 42: 49-75.
84. Rayssiguier Y, Gueux E. Magnesium and lipids in cardiovascular disease. J Am Coll Nutr 1986; 5: 507-19.
85. Shechter M, Merz CN, Rude RK, Paul Labrador MJ, Meisel SR, Shah PK, Kaul S. Low intracellular magnesium levels promote platelet-dependent thrombosis in patients with coronary artery disease. Am Heart J 2000; 140: 212-8.
86. Sharrett AR, Feinleib M. Water constituents and trace elements in relation to cardiovascular diseases. Prev Med 1975; 4: 20-36.
87. Sharrett AR. The role of chemical constituents of drinking water in cardiovascular diseases. Am J Epidemiol 1979; 110: 401-19.
88. Adachi M, Nara Y, Mano M, Ikeda K, Hone R, Yamori Y. Intralymphocytic free calcium and magnesium in stroke-prone spontaneously hypertensive rats and effects of blood pressure and various antihypertensive agents. Clin Exp Pharmacol Physiol 1993; 20: 587-93.
89. Altura BM, Altura BT, Carella A, Turlapaty PD. Hypomagnesemia and vasoconstriction: possible relationship to etiology of sudden death ischemic heart disease and hypertensive vascular diseases. Artery 1981; 9: 212-31.
90. Altura BM, Kostellow AB, Zhang A, Li W, Morrill GA, Gupta RK, Altura BT. Expression of the nuclear factor-kappaB and proto-oncogenes c-fos and c-jun are induced by low extracellular Mg2+ in aortic and cerebral vascular smooth muscle cells: possible links to hypertension, atherogenesis, and stroke. Am J Hypertens 2003; 16: 701-7.
91. Ameen M, Davies JE, Ng LL. A comparison of free intracellular calcium and magnesium levels in the vascular smooth muscle and striated muscle cells of the spontaneously hypertensive and Wistar Kyoto normotensive rat. Ann N Y Acad Sci 1991; 639: 550-3.
92. Berthelot A, Luthringer C, Meyers E, Exinger A. Disturbances of magnesium metabolism in the spontaneously hypertensive rat. J Am Coll Nutr 1987; 6: 329-32.
93. Berthon N, Laurant P, Fellmann D, Berthelot A. Effect of magnesium on mRNA expression and production of endothelin-1 in DOCA-salt hypertensive rats. J Cardiovasc Pharmacol 2003; 42: 24-31.
94. Kisters K, Krefting ER, Kosch M, Rahn KH, Hausberg M. Intracellular Mg++ concentrations in smooth and striated muscle cells in spontaneously hypertensive rats. Am J Hypertens 2000; 13: 427-30.
95. Kisters K, Krefting ER, Spieker C, Zidek W, Barenbrock M, Rahn KH. Increased Na+ and decreased Mg2+ intracellular concentrations in vascular smooth muscle cells from spontaneously hypertensive rats. Clin Sci (Lond) 1998; 95: 583-7.
96. Kisters K, Spieker C, Krefting ER, Scholz U, Tepel M, Zidek W, Barenbrock M. Electron-probe X-ray Microanalysis of Magnesium and Sodium Ion Content in Vascular Smooth Muscle Cells from Spontaneously Hypertensive and Normotensive Rats. Int J Angiol 1999; 8: 70-2.
97. Laurant P, Berthelot A. Endothelin-1-induced contraction in isolated aortae from normotensive and DOCA-salt hypertensive rats: effect of magnesium. Br J Pharmacol 1996; 119:1367-74.
98. Laurant P, Berthelot A. Influence of endothelium on Mg(2+)-induced relaxation in noradrenaline-contracted aorta from DOCA-salt hypertensive rat. Eur J Pharmacol 1994; 258:167-72.
99. Mahboob T, Mumtaz M, Haleem MA. Electrolyte content of serum, erythrocyte, kidney and heart tissue in salt induced hypertensive rats. Life Sci 1996; 59: 731-7.
100. Matuura T, Kohno M, Kanayama Y, Yasunari K, Murakawa K, Takeda T, Ishimori K, Morishima I, Yonezawa T. Decreased intracellular free magnesium in erythrocytes of spontaneously hypertensive rats. Biochem Biophys Res Commun 1987; 143: 1012-7.
101. Northcott CA, Watts SW. Low [Mg2+]e enhances arterial spontaneous tone via phosphatidylinositol 3-kinase in DOCA-salt hypertension. Hypertension 2004; 43: 125-9.
102. Rayssiguier Y, Mbega JD, Durlach V, Gueux E, Durlach J, Giry J, Dalle M, Mazur A, Laurant P, Berthelot A. Magnesium and blood pressure. I. Animal studies. Magnes Res 1992; 5: 139-46.
103. Wallach S, Verch RL. Tissue magnesium in spontaneously hypertensive rats. Magnesium 1986; 5: 33-8.
104. Buemi M, Corica F, Squadrito F, Ceruso D, Frisina N. Plasma and erythrocyte magnesium concentrations in essential arterial hypertension. Kidney Int Suppl 1988; 25: S14-S15.
105. Corica F, Allegra A, Ientile R, Buemi M. Magnesium concentrations in plasma, erythrocytes, and platelets in hypertensive and normotensive obese patients. Am J Hypertens 1997; 10: 1311-3.
106. Kisters K, Tepel M, Spieker C, Dietl KH, Barenbrock M, Rahn KH, Zidek W. Decreased cellular Mg2+ concentrations in a subgroup of hypertensives-cell models for the pathogenesis of primary hypertension. J Hum Hypertens 1997; 11: 367-72.
107. Kisters K, Tepel M, Spieker C, Zidek W, Barenbrock M, Tokmak F, Kosch M, Hausberg M, Rahn KH. Decreased membrane Mg2+ concentrations in a subgroup of hypertensives: membrane model for the pathogenesis of primary hypertension. Am J Hypertens 1998; 11: 1390-3.
108. Kosch M, Hausberg M, Westermann G, Koneke J, Matzkies F, Rahn KH, Kisters K. Alterations in calcium and magnesium content of red cell membranes in patients with primary hypertension. Am J Hypertens 2001; 14: 254-8.
109. Touyz RM. Role of magnesium in the pathogenesis of hypertension. Mol Aspects Med 2003; 24: 107-36.
110. Touyz RM. Magnesium and hypertension. Curr Opin Nephrol Hypertens 2006; 15: 141-4.
111. Touyz RM, Milne FJ, Reinach SG. Intracellular Mg2+, Ca2+, Na2+ and K+ in platelets and erythrocytes of essential hypertension patients: relation to blood pressure. Clin Exp Hypertens A 1992; 14: 1189-209.
112. Touyz RM, Milne FJ, Seftel HC, Reinach SG. Magnesium, calcium, sodium and potassium status in normotensive and hypertensive Johannesburg residents. S Afr Med J 1987; 72: 377-81.
113. Touyz RM, Panz V, Milne FJ. Relations between magnesium, calcium, and plasma renin activity in black and white hypertensive patients. Miner Electrolyte Metab 1995; 21: 417-22.
114. Gilles-Baillien M, Cogneau M. Magnesium uptake by intestinal brush-border membranes of spontaneously hypertensive rats. Proc Soc Exp Biol Med 1992; 201: 119-24.
115. Wells IC, Agrawal DK. Abnormal magnesium metabolism in two rat models of genetic hypertension. Can J Physiol Pharmacol 1992; 70: 1225-9.
116. Picado MJ, de la Sierra A, Aguilera MT, Coca A, Urbano-Marquez A. Increased activity of the Mg2+/Na+ exchanger in red blood cells from essential hypertensive patients. Hypertension 1994; 23: 987-91.
117. Touyz RM, Schiffrin EL. Activation of the Na(+)-H+ exchanger modulates angiotensin II-stimulated Na(+)-dependent Mg2+ transport in vascular smooth muscle cells in genetic hypertension. Hypertension 1999; 34: 442-9.
118. Touyz RM, Yao G. Inhibitors of Na+/Mg2+ exchange activity attenuate the development of hypertension in angiotensin II-induced hypertensive rats. J Hypertens 2003; 21: 337-44.
119. Hermansen K. Diet, blood pressure and hypertension. Br J Nutr 2000; 83(Suppl 1): S113-S119.
120. Mizushima S, Cappuccio FP, Nichols R, Elliott P. Dietary magnesium intake and blood pressure: a qualitative overview of the observational studies. J Hum Hypertens 1998; 12: 447-53.
121. Joffres MR, Reed DM, Yano K. Relationship of magnesium intake and other dietary factors to blood pressure: the Honolulu heart study. Am J Clin Nutr 1987; 45: 469-75.
122. Ma J, Folsom AR, Melnick SL, Eckfeldt JH, Sharrett AR, Nabulsi AA, Hutchinson RG, Metcalf PA. Associations of serum and dietary magnesium with cardiovascular disease, hypertension, diabetes, insulin, and carotid arterial wall thickness: the ARIC study. Atherosclerosis Risk in Communities Study. J Clin Epidemiol 1995; 48: 927-40.
123. Peacock JM, Folsom AR, Arnett DK, Eckfeldt JH, SzkIo M. Relationship of serum and dietary magnesium to incident hypertension: the Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol 1999; 9: 159-65.
124. Song Y, Sesso HD, Manson JE, Cook NR, Buring JE, Liu S. Dietary magnesium intake and risk of incident hypertension among middle-aged and older US women in a 10-year follow-up study. Am J Cardiol 2006; 98: 1616-21.
125. Simons-Morton DG, Hunsberger SA, Van Horn L, Barton BA, Robson AM, McMahon RP, Muhonen LE, Kwiterovich PO, Lasser NL, Kimm SY, Greenlick MR. Nutrient intake and blood pressure in the Dietary Intervention Study in Children. Hypertension 1997; 29: 930-6.
126. Kesteloot H, Joossens JV. Relationship of dietary sodium, potassium, calcium, and magnesium with blood pressure. Belgian Interuniversity Research on Nutrition and Health. Hypertension 1988; 12: 594-9.
127. Blache D, Devaux S, Joubert O, Loreau N, Schneider M, Durand P, Prost M, Gaume V, Adrian M, Laurant P, Berthelot A. Long-term moderate magnesium-deficient diet shows relationships between blood pressure, inflammation and oxidant stress defense in aging rats. Free Radic Biol Med 2006; 41: 277-84.
128. Laurant P, Hayoz D, Brunner HR, Berthelot A. Effect of magnesium deficiency on blood pressure and mechanical properties of rat carotid artery. Hypertension 1999; 33: 1105-10.
129. Laurant P, Robin S, Berthelot A. Magnesium deficiency increases vasoconstrictor activity without affecting blood pressure of aged spontaneously hypertensive rats. Magnes Res 1997; 10: 107-17.
130. Luthringer C, Rayssiguier Y, Gueux E, Berthelot A. Effect of moderate magnesium deficiency on serum lipids, blood pressure and cardiovascular reactivity in normotensive rats. Br J Nutr 1988; 59: 243-50.
131. Maier JA, Malpuech-Brugere C, Zimowska W, Rayssiguier Y, Mazur A. Low magnesium promotes endothelial cell dysfunction: implications for atherosclerosis, inflammation and thrombosis. Biochim Biophys Acta 2004; 1689: 13-21.
132. Murasato Y, Harada Y, Ikeda M, Nakashima Y, Hayashida Y. Effect of magnesium deficiency on autonomic circulatory regulation in conscious rats. Hypertension 1999; 34: 247-52.
133. Adrian M, Laurant P, Berthelot A. Effect of magnesium on mechanical properties of pressurized mesenteric small arteries from old and adult rats. Clin Exp Pharmacol Physiol 2004; 31: 306-13.
134. Tammaro P, Smith AL, Crowley BL, Smirnov SV. Modulation of the voltage-dependent K+ current by intracellular Mg2+ in rat aortic smooth muscle cells. Cardiovasc Res 2005; 65: 387-96.
135. Gamble J, Blackfan KD, Hamilton B. A Study of the Diuretic Action of Acid Producing Salts. J Clin Invest 1925: 359-88.
136. Dyckner T, Wester PO. Effect of magnesium on blood pressure. Br Med J (Clin Res Ed) 1983; 286: 1847-9.
137. Lind L, Lithell H, Pollare T, Ljunghall S. Blood pressure response during long-term treatment with magnesium is dependent on magnesium status. A double-blind, placebo-controlled study in essential hypertension and in subjects with high-normal blood pressure. Am J Hypertens 1991; 4: 674-9.
138. Ryan MP, Brady HR. The role of magnesium in the prevention and control of hypertension. Ann Clin Res 1984; 16(Suppl 43): 81-8.
139. Widman L, Wester PO, Stegmayr BK, Wirell M. The dose-dependent reduction in blood pressure through administration of magnesium. A double blind placebo controlled cross-over study. Am J Hypertens 1993; 6: 41-5.
140. Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, Smith D. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002; 359: 1877-90.
141. Yamamoto ME, Applegate WB, Klag MJ, Borhani NO, Cohen JD, Kirchner KA, Lakatos E, Sacks FM, Taylor JO, Hennekens CH. Lack of blood pressure effect with calcium and magnesium supplementation in adults with high-normal blood pressure. Results from Phase I of the Trials of Hypertension Prevention (TOHP). Trials of Hypertension Prevention (TOHP) Collaborative Research Group. Ann Epidemiol 1995; 5: 96-107.
142. Jee SH, Miller 3rd ER, Guallar E, Singh VK, Appel LJ, Flag MJ. The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials. Am J Hypertena 2002; 15: 691-6.
143. Altura BM, Altura BT. Magnesium ions and contraction of vascular smooth muscles: relationship to some vascular diseases. Fed Proc 1981; 40: 2672-9.
144. Yang Z, Wang J, Altura BT, Altura BM. Extracellular magnesium deficiency induces contraction of arterial muscle: role of PI3-kinases and MAPK signaling pathways. Pflugers Arch 2000; 439: 240-7.
145. Yang ZW, Altura BT, Altura BM. Low extracellular Mg2+ contraction of arterial muscle: role of protein kinase C and protein tyrosine phosphorylation. Eur J Pharmacol 1999; 378: 273-81.
146. Yang ZW, Wang J, Zheng T, Altura BT, Altura BM. Low [Mg(2+)](o) induces contraction of cerebral arteries: roles of tyrosine and mitogen-activated protein kinases. Am J Physiol Heart Circ Physiol 2000; 279: H185-H194.
147. Yang ZW, Wang J, Zheng T, Altura BT, Altura BM. Low [Mg(2+)](o) induces contraction and [Ca(2+)](i) rises in cerebral arteries: roles of ca(2+), PKC, and PI3. Am J Physiol Heart Circ Physiol 2000; 279: H2898-H2907.
148. Howard AB, Alexander RW, Taylor WR. Effects of magnesium on nitric oxide synthase activity in endothelial cells. Am J Physiol 1995; 269: C612-C618.
149. O'Brien WF, Williams MC, Benoit R, Sawai SK, Knuppel RA. The effect of magnesium sulfate infusion on systemic and renal prostacyclin production. Prostaglandins 1990; 40: 529-38.
150. Yang ZW, Gebrewold A, Nowakowski M, Altura BT, Altura BM. Mg(2+)-induced endothelium-dependent relaxation of blood vessels and blood pressure lowering: role of NO. Am J Physiol Regul Integr Comp Physiol 2000; 278: R628-R639.
151. Pearson PJ, Evora PR, Seccombe JF, Schaff HV. Hypomagnesemia inhibits nitric oxide release from coronary endothelium: protective role of magnesium infusion after cardiac operations. Ann Thorac Surg 1998; 65: 967-72.
152. Maier JA, Bernardini D, Rayssiguier Y, Mazur A. High concentrations of magnesium modulate vascular endothelial cell behaviour in vitro. Biochim Biophys Acta 2004; 1689: 6-12.
153. Ramchandra R, Barrett CJ, Malpas SC. Nitric oxide and sympathetic nerve activity in the control of blood pressure. Clin Exp Pharmacol Physiol 2005; 32: 440-6.
154. Briel RC, Lippert TH, Zahradnik HP. Action of magnesium sulfate on platelet prostacyclin interaction and prostacyclin of blood vessels. Am J Obstet Gynecol 1985; 153: 232.
155. Satake K, Lee JD, Shimizu H, Uzui H, Mitsuke Y, Yue H, Ueda T. Effects of magnesium on prostacyclin synthesis and intracellular free calcium concentration in vascular cells. Magnes Res 2004; 17: 20-7.
156. Watson KV, Moldow CF, Ogburn PL, Jacob HS. Magnesium sulfate: rationale for its use in preeclampsia. Proc Natl Acad Sci USA 1986; 83: 1075-8.
157. Laurant P, Berthelot A. Arch Mal Coeur Vaiss 1992; 85: 1223-6; [In vitro study of the role of endothelium on the vasorelaxant effect of magnesium on the aorta from DOCA-salt hypertensive rats].
158. Angerio AD. The role of endothelin in heart failure. Crit Care Nurs Q 2005; 28: 355-9.
159. Berthon N, Laurant P, Hayoz D, Fellmann D, Brunner HR, Berthelot A. Magnesium supplementation and deoxycorticosterone acetate - salt hypertension: effect on arterial mechanical properties and on activity of endothelin-1. Can J Physiol Pharmacol 2002; 80: 553-61.
160. Weglicki WB, Phillips TM, Freedman AM, Cassidy MM, Dickens BF. Magnesium-deficiency elevates circulating levels of inflammatory cytokines and endothelin. Mol Cell Biochem 1992; 110: 169-73.
161. Prasad A, Quyyumi AA. Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation 2004; 110: 1507-12.
162. Corica F, Corsonello A, Buemi M, De Gregorio T, Malara A, Mauro VN, Macaione S, Ientile R. Platelet magnesium depletion in normotensive and hypertensive obese subjects: the role of salt-regulating hormones and catecholamines. Magnes Res 1999; 12: 287-96.
163. Resnick LM, Laragh JH, Sealey JE, Alderman MH. Divalent cations in essential hypertension. Relations between serum ionized calcium, magnesium, and plasma renin activity. N Engl J Med 1983; 309: 888-91.
164. Ichihara A, Suzuki H, Saruta T. Effects of magnesium on the renin-angiotensin-aldosterone system in human subjects. J Lab Clin Med 1993; 122: 432-40.
165. Laurant P, Dalle M, Berthelot A, Rayssiguier Y. Time-course of the change in blood pressure level in magnesium-deficient Wistar rats. Br J Nutr 1999; 82: 243-51.
166. Altura BM, Altura BT, Carella A. Magnesium deficiency-induced spasms of umbilical vessels: relation to preeclampsia, hypertension, growth retardation. Science 1983; 221: 376-8.
167. Shimosawa T, Takano K, Ando K, Fujita T. Magnesium inhibits norepinephrine release by blocking N-type calcium channels at peripheral sympathetic nerve endings. Hypertension 2004; 44: 897-902.
168. Touyz RM, Laurant P, Schiffrin EL. Effect of magnesium on calcium responses to vasopressin in vascular smooth muscle cells of spontaneously hypertensive rats. J Pharmacol Exp Ther 1998; 284: 998-1005.
169. De Martin R, Hoeth M, Hofer-Warbinek R, Schmid JA. The transcription factor NF-kappa B and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol 2000; 20: E83-E88.
170. Colditz GA, Manson JE, Stampfer MJ, Rosner B, Willett WC, Speizer FE. Diet and risk of clinical diabetes in women. Am J Clin Nutr 1992; 55: 1018-23.
171. Kao WH, Folsom AR, Nieto FJ, Mo JP, Watson RL, Brancati FL. Serum and dietary magnesium and the risk for type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study. Arch Intern Med 1999; 159: 2151-9.
172. Lima Mde L, Pousada J, Barbosa C, Cruz T. Arq Bras Endocrinol Metabol 2005; 49: 959-63; [Magnesium deficiency and insulin resistance in patients with type 2 diabetes mellitus].
173. Lopez-Ridaura R, Willett WC, Rimm EB, Liu S, Stampfer MJ, Manson JE, Hu FB. Magnesium intake and risk of type 2 diabetes in men and women. Diabetes Care 2004; 27: 134-40.
174. Song Y, Manson JE, Buring JE, Liu S. Dietary magnesium intake in relation to plasma insulin levels and risk of type 2 diabetes in women. Diabetes Care 2004; 27: 59-65.
175. van Dam RM, Hu FB, Rosenberg L, Krishnan S, Palmer JR. Dietary calcium and magnesium, major food sources, and risk of type 2 diabetes in U.S. black women. Diabetes Care 2006; 29: 2238-43.
176. Corica F, Ientile R, Allegra A, Romano G, Cangemi F, Di Benedetto A, Buemi M, Cucinotta D, Ceruso D. Magnesium levels in plasma, erythrocyte, and platelet in hypertensive and normotensive patients with type II diabetes mellitus. Biol Trace Elem Res 1996; 51: 13-21.
177. Paolisso G, Barbagallo M. Hypertension, diabetes mellitus, and insulin resistance: the role of intracellular magnesium. Am J Hypertens 1997; 10: 346-55.
178. Paolisso G, Ravussin E. Intracellular magnesium and insulin resistance: results in Pima Indians and Caucasians. J Clin Endocrinol Metab 1995; 80: 1382-5.
179. Resnick LM, Altura BT, Gupta RK, Laragh JH, Alderman MH, Altura BM. Intracellular and extracellular magnesium depletion in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1993; 36: 767-70.
180. Schnack C, Bauer I, Pregant P, Hopmeier P, Schernthaner G. Hypomagnesaemia in type 2 (non-insulin-dependent) diabetes mellitus is not corrected by improvement of long-term metabolic control. Diabetologia 1992; 35: 77-9.
181. Reinhart RA, Marx Jr. JJ, Broste SK, Haas RG. Myocardial magnesium: relation to laboratory and clinical variables in patients undergoing cardiac surgery. J Am Coll Cardiol 1991; 17: 651-6.
182. Djurhuus MS, Skott P, Hother-Nielson O, Klitgaard NA, Beck-Nielsen H. Insulin increases renal magnesium excretion: a possible cause of magnesium depletion in hyperinsulinaemic states. Diabet Med 1995; 12: 664-9.
183. Djurhuus MS. New data on the mechanisms of hypermagnesuria in type I diabetes mellitus. Magnes Res 2001; 14: 217-23.
184. Paolisso G, Scheen A, Cozzolino D, Di Maro G, Varricchio M, D'Onofrio F, Lefebvre PJ. Changes in glucose turnover parameters and improvement of glucose oxidation after 4-week magnesium administration in elderly noninsulin-dependent (type II) diabetic patients. J Clin Endocrinol Metab 1994; 78: 1510-4.
185. Rodriguez-Moran M, Guerrero-Romero F. Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. Diabetes Care 2003; 26: 1147-52.
186. Song Y, He K, Levitan EB, Manson JE, Liu S. Effects of oral magnesium supplementation on glycaemic control in Type 2 diabetes: a meta-analysis of randomized double-blind controlled trials. Diabet Med 2006; 23: 1050-6.
187. Laughlin MR, Thompson D. The regulatory role for magnesium in glycolytic flux of the human erythrocyte. J Biol Chem 1996; 271: 28977-83.
188. Barbagallo M, Dominguez LJ, Galioto A, Ferlisi A, Cani C, Malfa L, Pineo A, Busardo A, Paolisso G. Role of magnesium in insulin action, diabetes and cardiometabolic syndrome X. Mol Aspects Med 2003; 24: 39-52.
189. Suarez A, Pulido N, Casla A, Casanova B, Arrieta FJ, Rovira A. Impaired tyrosine-kinase activity of muscle insulin receptors from hypomagnesaemic rats. Diabetologia 1995; 38: 1262-70.
190. Paxton R, Ye L. Regulation of heart insulin receptor tyrosine kinase activity by magnesium and spermine. Mol Cell Biochem 2005; 277: 7-17.
191. McCarty MF. PKC-mediated modulation of L-type calcium channels may contribute to fat-induced insulin resistance. Med Hypotheses 2006; 66: 824-31.
192. McCarty MF. Up-regulation of intracellular signalling pathways may play a central pathogenic role in hypertension, atherogenesis, insulin resistance, and cancer promotion-the 'PKC syndrome'. Med Hypotheses 1996; 46: 191-221.
193. Gueux E, Rayssiguier Y. The effect of magnesium deficiency on glucose stimulated insulin secretion in rats. Horm Metab Res 1983; 15: 594-7.
194. Ziegler B, Wilke B, Woltanski KP, Knospe S, Hahn HJ. Protection of insulin secretion by magnesium during islet culture: independence of cAMP/or insulin accumulation. Exp Clin Endocrinol 1983; 82:199-207.
195. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-26.
196. Ueshima K. Magnesium and ischemic heart disease: a review of epidemiological, experimental, and clinical evidences. Magnes Res 2005; 18: 275-84.
197. Chipperfield B, Chipperfield JR. Heart-muscle magnesium, potassium, and zinc concentrations after sudden death from heart-disease. Lancet 1973; 2: 293-6.
198. Elwood PC, Beasley WH. Myocardial magnesium and ischaemic heart disease. Artery 1981; 9: 200-4.
199. Iskra M, Majewski W, Piorunska-Stolzmann M. Modifications of magnesium and copper concentrations in serum and arterial wall of patients with vascular diseases related to ageing, atherosclerosis and aortic aneurysm. Magnes Res 2002; 15: 279-85.
200. Vlad M, Uza G, Porr PJ, Caseanu E, Petrescu M. Magnesium and calcium concentration in the abdominal aorta of patients deceased by ischemic heart disease. Magnes Res 2000; 13: 37-41.
201. Millane TA, Jennison SH, Mann JM, Holt DW, McKenna WJ, Camm AJ. Myocardial magnesium depletion associated with prolonged hypomagnesemia: a longitudinal study in heart transplant recipients. J Am Coll Cardiol 1992; 20: 806-12.
202. Abbott RD, Ando F, Masaki KH, Tung KH, Rodriguez BL, Petrovitch H, Yano K, Curb JD. Dietary magnesium intake and the future risk of coronary heart disease (the Honolulu Heart Program). Am J Cardiol 2003; 92: 665-9.
203. Liao F, Folsom AR, Brancati FL. Is low magnesium concentration a risk factor for coronary heart disease? The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 1998; 136: 480-90.
204. Rasmussen HS, Aurup P, Goldstein K, McNair P, Mortensen PB, Larsen OG, Lawaetz H. Influence of magnesium substitution therapy on blood lipid composition in patients with ischemic heart disease. A double-blind, placebo controlled study. Arch Intern Med 1989; 149: 1050-3.
205. Singh RB, Rastogi SS, Mani UV, Seth J, Devi L. Does dietary magnesium modulate blood lipids? Biol Trace Elem Res 1991; 30: 59-64.
206. Singh RB, Rastogi SS, Sharma VK, Saharia RB, Kulshretha SK. Can dietary magnesium modulate lipoprotein metabolism? Magnes Trace Elem 1990; 9: 255-64.
207. Cohen H, Sherer Y, Shaish A, Shoenfeld Y, Levkovitz H, Bitzur R, Harats D. Atherogenesis inhibition induced by magnesium-chloride fortification of drinking water. Biol Trace Elem Res 2002; 90: 251-9.
208. Ravn HB, Korshohn TL, Falk E. Oral magnesium supplementation induces favorable antiatherogenic changes in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2001; 21: 858-62.
209. Sherer Y, Bitzur R, Cohen H, Shaish A, Varon D, Shoenfeld Y, Harats D. Mechanisms of action of the anti-atherogenic effect of magnesium: lessons from a mouse model. Magnes Res 2001; 14: 173-9.
210. Sherer Y, Shaish A, Levkovit zH, Keren P, Janackovic Z, Shoenfeld Y, Harats D. Magnesium fortification of drinking water suppresses atherogenesis in male LDL-receptor-deficient mice. Pathobiology 1999; 67: 207-13.
211. Sherer Y, Shoenfeld Y, Shaish A, Levkovitz H, Bitzur R, Harats D. Suppression of atherogenesis in female low-density lipoprotein receptor knockout mice following magnesium fortification of drinking water: the importance of diet. Pathobiology 2000; 68: 93-8.
212. Altura BT, Brust M, Bloom S, Barbour RL, Stempak JG, Altura BM. Magnesium dietary intake modulates blood lipid levels and atherogenesis. Proc Natl Acad Sci USA 1990; 87: 1840-4.
213. Evans DA, Tariq M, Sujata B, McCann G, Sobki S. The effects of magnesium sulphate and EDTA in the hypercholesterolaemic rabbit. Diabetes Obes Metab 2001; 3: 417-22.
214. Atabek ME, Kurtoglu S, Pirgon O, Baykara M. Serum magnesium concentrations in type 1 diabetic patients: relation to early atherosclerosis. Diabetes Res Clin Pract 2006; 72: 42-7.
215. Tzanakis I, Virvidakis K, Tsomi A, Mantakas E, Girousis N, Karefyllakis N, Papadaki A, Kallivretakis N, Mountokalakis T. Intra- and extracellular magnesium levels and atheromatosis in haemodialysis patients. Magnes Res 2004; 17: 102-8.
216. Hasham SN, Pillarisetti S. Vascular lipases, inflammation and atherosclerosis. Clin Chim Acta 2006; 372: 179-83.
217. Rayssiguier Y, Noe L, Etienne J, Gueux E, Cardot P, Mazur A. Effect of magnesium deficiency on post-heparin lipase activity and tissue lipoprotein lipase in the rat. Lipids 1991; 26: 182-6.
218. Field FJ, Henning B, Mathur SN. In vitro regulation of 3-hydroxy-3-methylglutarylcoenzyme A reductase and acylcoenzyme A: cholesterol acyltransferase activities by phosphorylation-dephosphorylation in rabbit intestine. Biochim Biophys Acta 1984; 802: 9-16.
219. Jonas A. Lecithin cholesterol acyltransferase. Biochim Biophys Acta 2000; 1529: 245-56.
220. Rayssiguier Y. Magnesium, lipids and vascular diseases. Experimental evidence in animal models. Magnesium 1986; 5: 182-90.
221. Gueux E, Rayssiguier Y, Piot MC, Alcindor L. Reduction of plasma lecithin-cholesterol acyltransferase activity by acute magnesium deficiency in the rat. J Nutr 1984; 114: 1479-83.
222. Nozue T, Ide N, Okabe H, Narui K, Kobayashi A. Correlation of serum HDL-cholesterol and LCAT levels with the fraction of ionized magnesium in children. Magnes Res 1999; 12: 297-301.
223. Mahfouz MM, Kummerow FA. Effect of magnesium deficiency on delta 6 desaturase activity and fatty acid composition of rat liver microsomes. Lipids 1989; 24: 727-32.
224. Rosanoff A, Seelig MS. Comparison of mechanism and functional effects of magnesium and statin pharmaceuticals. J Am Coll Nutr 2004; 23: 501S-505S.
225. Gueux E, Azais-Braesco V, Bussiere L, Grolier P, Mazur A, Rayssiguier Y. Effect of magnesium deficiency on triacylglycerol-rich lipoprotein and tissue susceptibility to peroxidation in relation to vitamin E content. Br J Nutr 1995; 74: 849-56.
226. Gueux E, Cubizolles C, Bussiere L, Mazur A, Rayssiguier Y. Oxidative modification of triglyceride-rich lipoproteins in hypertriglyceridemic rats following magnesium deficiency. Lipids 1993; 28: 573-5.
227. Bussiere L, Mazur A, Gueux E, Nowacki W, Rayssiguier Y. Triglyceride-rich lipoproteins from magnesium-deficient rats are more susceptible to oxidation by cells and promote proliferation of cultured vascular smooth muscle cells. Magnes Res 1995; 8: 151-7.
228. Mahfouz MM, Zhou Q, Kummerow FA. Cholesterol oxides in plasma and lipoproteins of magnesium-deficient rabbits and effects of their lipoproteins on endothelial barrier function. Magnes Res 1994; 7: 207-22.
229. Yokoyama S, Nishida HI, Smith TL, Kummerow FA. Combined effects of magnesium deficiency and an atherogenic level of low density lipoprotein on uptake and metabolism of low density lipoprotein by cultured human endothelial cells. I. Biochemical data. Magnes Res 1994; 7: 87-95.
230. Bernardini D, Nasulewic A, Mazur A, Maier JA. Magnesium and microvascular endothelial cells: a role in inflammation and angiogenesis. Front Biosci 2005; 10: 1177-82.
231. Guo H, Lee JD, Uzui H, Yue H, Wang J, Toyoda K, Geshi T, Ueda T. Effects of folic acid and magnesium on the production of homocysteine-induced extracellular matrix metalloproteinase-2 in cultured rat vascular smooth muscle cells. Circ J 2006; 70: 141-6.
232. Yue H, Lee JD, Shimizu H, Uzui H, Mitsuke Y, Ueda T. Effects of magnesium on the production of extracellular matrix metalloproteinases in cultured rat vascular smooth muscle cells. Atherosclerosis 2003; 166: 271-7.
233. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25: 4-7.
234. Vaskonen T. Dietary minerals and modification of cardiovascular risk factors. J Nutr Biochem 2003; 14: 492-506.
235. Lelovics Z. Relation between calcium and magnesium intake and obesity. Asia Pac J Clin Nutr 2004; 13: S144.
236. Rodriguez-Hernandez H, Gonzalez JL, Rodriguez-Moran M, Guerrero-Romero F. Hypomagnesemia, insulin resistance, and non-alcoholic steatohepatitis in obese subjects. Arch Med Res 2005; 36: 362-6.
237. Yakinci C, Pac A, Kucukbay FZ, Tayfun M, Gul A. Serum zinc, copper, and magnesium levels in obese children. Acta Paediatr Jpn 1997; 39: 339-41.
238. Mataix J, Aranda P, Lopez-Jurado M, Sanchez C, Planells E, Llopis J. Factors influencing the intake and plasma levels of calcium, phosphorus and magnesium in southern Spain. Eur J Nutr 2006; 45: 349-54.
239. Singh RB, Beegom R, Rastogi SS, Gaoli Z, Shoumin Z. Association of low plasma concentrations of antioxidant vitamins, magnesium and zinc with high body fat per cent measured by bioelectrical impedance analysis in Indian men. Magnes Res 1998; 11: 3-10.
240. Mazur A, Gueux E, Remesy C, Demigne C, Rayssiguier Y. Plasma and red blood cell magnesium concentrations in Zucker rats: influence of a high fibre diet. Magnes Res 1989; 2: 189-92.
241. Begin-Heick N. The effect of the divalent cations Mg2+ and Mn2+ on adenylate cyclase activity in white and brown adipose tissue of lean and obese (ob/ob) mice. Can J Biochem Cell Biol 1985; 63: 7-15.
242. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006; 444: 847-53.
243. Kandeel FR, Balon E, Scott S, Nadler JL. Magnesium deficiency and glucose metabolism in rat adipocytes. Metabolism 1996; 45: 838-43.
244. Festa A, D'Agostino Jr. R, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002; 51: 1131-7.
245. Schneider DJ. Abnormalities of coagulation, platelet function, and fibrinolysis associated with syndromes of insulin resistance. Coron Artery Dis 2005; 16: 473-6.
246. Corica F, Allegra A, Buemi M, Ientile R, Corsonello A, Di Benedetto A, Bonanzinga S, Ruello A, D'Angelo R, Cucinotta D, Ceruso D. Altered platelet magnesium and plasma and urinary soluble form of intercellular adhesion molecule I (sICAM-1) concentrations in insulin dependent diabetes mellitus (IDDM) patients with microalbuminuria Magnes Res 1996; 9: 307-12.
247. Nadler JL, Malayan S, Luong H, Shaw S, Natarajan RD, Rude RK. Intracellular free magnesium deficiency plays a key role in increased platelet reactivity in type II diabetes mellitus. Diabetes Care 1992; 15: 835-41.
248. Takaya J, Higashino H, Kotera F, Kobayashi Y. Intracellular magnesium of platelets in children with diabetes and obesity. Metabolism 2003; 52: 468-71.
249. Teo KK, Yusuf S, Collins R, Held PH, Peto R. Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials. BMJ 1991; 303: 1499-503.
250. Woods KL, Fletcher S. Long-term outcome after intravenous magnesium sulphate in suspected acute myocardial infarction: the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1994; 343: 816-9.
251. Gawaz M, Reininger A, Neumann FJ. Platelet function and platelet-leukocyte adhesion in symptomatic coronary heart disease. Effects of intravenous magnesium. Thromb Res 1996; 83: 341-9.
252. Shechter M. The role of magnesium as antithrombotic therapy. Wien Med Wochenschr 2000; 150: 343-7.
253. Sheu JR, Hsiao G, Shen MY, Lee YM, Yen MH. Anti-thrombotic effects of magnesium sulfate in in vivo experiments. Int J Hematol 2003; 77: 414-9.
254. Gries A, Bode C, Gross S, Peter K, Bohrer H, Martin E. The effect of intravenously administered magnesium on platelet function in patients after cardiac surgery. Anesth Analg 1999; 88: 1213-9.
255. Sheu JR, Hsiao G, Shen MY, Fong TH, Chen YW, Lin CH, Chou DS. Mechanisms involved in the anti-platelet activity of magnesium in human platelets. Br J Haematol 2002; 119: 1033-41.
256. Ravn HB, Vissinger H, Kristensen SD, Wennmalm A, Thygesen K, Husted SE. Magnesium inhibits platelet activity-an infusion study in healthy volunteers. Thromb Haemost 1996; 75: 939-44.
257. Hsiao G, Shen MY, Chou DS, Lin CH, Chen TF, Sheu JR. Involvement of the antiplatelet activity of magnesium sulfate in suppression of protein kinase C and the Na+/H+ exchanger. J Biomed Sci 2004; 11: 19-26.
258. Nadler JL, Buchanan T, Natarajan R, Antonipillai I, Bergman R, Rude R. Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. Hypertension 1993; 21: 1024-9.
259. Ravn HB, Vissinger H, Kristensen SD, Husted SE. Magnesium inhibits platelet activity-an in vitro study. Thromb Haemost 1996; 76: 88-93.
260. Barzilay J, Freedland E. Inflammation and its association with glucose disorders and cardiovascular disease. Treat Endocrinol 2003; 2: 85-94.
261. Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, Tracy RP. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001; 50: 2384-9.
262. Ridker PM. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol 2003; 92: 17K-22K.
263. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.
264. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101: 2149-53.
265. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-72.
266. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 2003; 290: 2945-51.
267. Rodriguez-Moran M, Guerrero-Romero F. Increased levels of C-reactive protein in noncontrolled type II diabetic subjects. J Diabetes Complications 1999; 13: 211-5.
268. Aso Y, Wakabayashi S, Yamamoto R, Matsutomo R, Takebayashi K, Inukai T. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor. Diabetes Care 2005; 28: 2211-6.
269. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-7.
270. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
271. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95: 2111-9.
272. Mantzoros CS, Moschos S, Avramopoulos I, Kaklamani V, Liolios A, Doulgerakis DE, Griveas I, Katsilambros N, Flier JS. Leptin concentrations in relation to body mass index and the tumor necrosis factor-alpha system in humans. J Clin Endocrinol Metab 1997; 82: 3408-13.
273. Yang WS, Chuang LM. Human genetics of adiponectin in the metabolic syndrome. J Mol Med 2006; 84: 112-21.
274. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
275. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-9.
276. Kazumi T, Kawaguchi A, Sakai K, Hirano T, Yoshino G. Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care 2002; 25: 971-6.
277. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004; 24: 29-33.
278. Ford ES, Ajani UA, Mokdad AH. The metabolic syndrome and concentrations of C-reactive protein among U.S. youth. Diabetes Care 2005; 28: 878-81.
279. Cankurtaran M, Halil M, Yavuz BB, Dagli N, Oyan B, Ariogul S. Prevalence and correlates of metabolic syndrome (MS) in older adults. Arch Gerontol Geriatr 2006; 42: 35-45.
280. Nakanishi N, Shiraishi T, Wada M. C-reactive protein concentration is more strongly related to metabolic syndrome in women than in men: the Minoh Study. Circ J 2005; 69: 386-91.
281. Saijo Y, Kiyota N, Kawasaki Y, Miyazaki Y, Kashimura J, Fukuda M, Kishi R. Relationship between C-reactive protein and visceral adipose tissue in healthy Japanese subjects. Diabetes Obes Metab 2004; 6: 249-58.
282. Tamakoshi K, Yatsuya H, Kondo T, Hori Y, Ishikawa M, Zhang H, Murata C, Otsuka R, Zhu S, Toyoshima H. The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state. Int J Obes Relat Metab Disord 2003; 27: 443-9.
283. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002; 25: 2016-21.
284. Laaksonen DE, Niskanen L, Nyyssonen K, Punnonen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 2004; 47: 1403-10.
285. King DE, Mainous 3rd AG, Geesey ME, Woolson RF. Dietary magnesium and C-reactive protein levels. J Am Coll Nutr 2005; 24: 166-71.
286. Qi L, Rimm E, Liu S, Rifai N, Hu FB. Dietary glycemic index, glycemic load, cereal fiber, and plasma adiponectin concentration in diabetic men. Diabetes Care 2005; 28: 1022-8.
287. King D, Mainous A, Geesey M, Ellis T. Magnesium intake and serum C-reactive protein levels in children. Magnes Res 2007; 20: 32-6.
288. Guerrero-Romero F, Rodriguez-Moran M. Relationship between serum magnesium levels and C-reactive protein concentration, in non-diabetic, non-hypertensive obese subjects. Int J Obes Relat Metab Disord 2002; 26: 469-74.
289. Rodriguez-Moran M, Guerrero-Romero F. Elevated concentrations of TNF-alpha are related to low serum magnesium levels in obese subjects. Magnes Res 2004; 17: 189-96.
290. Bernstein LE, Berry J, Kim S, Canavan B, Grinspoon SK. Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med 2006; 166: 902-8.
291. Kramer JH, Mak IT, Phillips TM, Weglicki WB. Dietary magnesium intake influences circulating proinflammatory neuropeptide levels and loss of myocardial tolerance to postischemic stress. Exp Biol Med (Maywood) 2003; 228: 665-73.
292. Malpuech-Brugere C, Nowacki W, Daveau M, Gueux E, Ldnard C, Rock E, Lebreton J, Mazur A, RayssiguierY. Inflammatory response following acute magnesium deficiency in the rat. Biochim Biophys Acta 2000; 1501: 91-8.
293. Malpuech-Brugere C, Nowacki W, Gueux E, Kuryszko J, Rock E, Rayssiguier Y, Mazur A. Accelerated thymus involution in magnesium-deficient rats is related to enhanced apoptosis and sensitivity to oxidative stress. Br J Nutr 1999; 81: 405-11.
294. Malpuech-Brugere C, Nowacki W, Rock E, Gueux E, Mazur A, Rayssiguier Y. Enhanced tumor necrosis factor-alpha production following endotoxin challenge in rats is an early event during magnesium deficiency. Biochim Biophys Acta 1999; 1453: 35-40.
295. Petrault I, Zimowska W, Mathieu J, Bayle D, Rock E, Favier A, Rayssiguier Y, Mazur A. Changes in gene expression in rat thymocytes identified by cDNA array support the occurrence of oxidative stress in early magnesium deficiency. Biochim Biophys Acta 2002; 1586: 92-8.
296. Weglicki WB, Phillips TM. Pathobiology of magnesium deficiency: a cytokine/neurogenic inflammation hypothesis. Am J Physiol 1992; 263: R734-R737.
297. Kurantsin-Mills J, Cassidy MM, Stafford RE, Weglicki WB. Marked alterations in circulating inflammatory cells during cardiomyopathy development in a magnesium-deficient rat model. Br J Nutr 1997; 78: 845-55.
298. Bussiere FI, Tridon A, Zimowska W, Mazur A, Rayssiguier Y. Increase in complement component C3 is an early response to experimental magnesium deficiency in rats. Life Sci 2003; 73: 499-507.
299. Nakagawa M, Ike T, Kawabe K, Fujii M, Miyamoto A, Ishiguro S, Nishio A. In vivo and in vitro effects of magnesium deficiency on hepatic haptoglobin mRNA levels. Magnes Res 2001; 14: 19-25.
300. Oono H, Nakagawa M, Miyamoto A, Ishiguro S, Nishio A. Mechanisms underlying the enhanced elevation of IL-1beta and TNF-alpha mRNA levels following endotoxin challenge in rat alveolar macrophages cultured with low-Mg2+ medium. Magnes Res 2002; 15: 153-60.
301. Tchoukalova YD, Grider A, Mouat MF, Hausman GJ. Priming with magnesium-deficient media inhibits preadipocyte differentiation via potential upregulation of tumor necrosis factor-alpha. Biol Trace Elem Res 2000; 74: 11-21.
302. Lee DS, Evans JC, Robins SJ, Wilson PW, Albano I, Fox CS, Wang TJ, Benjamin EJ, D'Agostino RB, Vasan RS. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2007; 27: 127-33.
303. Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 2001; 17: 189-212.
304. Evans JL, Maddux BA, Goldfine ID. The molecular basis for oxidative stress-induced insulin resistance. Antioxid Redox Signal 2005; 7: 1040-52.
305. Barbagallo M, Dominguez LJ, Tagliamonte MR, Resnick LM, Paolisso G. Effects of vitamin E and glutathione on glucose metabolism: role of magnesium. Hypertension 1999; 34: 1002-6.
306. Paolisso G, D'Amore A, Balbi V, Volpe C, Galzerano D, Giugliano D, Sgambato S, Varricchio M, D'Onofrio F. Plasma vitamin C affects glucose homeostasis in healthy subjects and in non-insulin-dependent diabetics. Am J Physiol 1994; 266: E261-E268.
307. Paolisso G, Tagliamonte MR, Barbieri M, Zito GA, Gambardella A, Varricchio G, Ragno E, Varricchio M. Chronic vitamin E administration improves brachial reactivity and increases intracellular magnesium concentration in type II diabetic patients. J Clin Endocrinol Metab 2000; 85: 109-15.
308. Weglicki WB, Mak IT, Kramer JH, Dickens BF, Cassidy MM, Stafford RE, Philips TM. Role of free radicals and substance P in magnesium deficiency. Cardiovasc Res 1996; 31: 677-82.
309. Nasulewicz A, Zimowska W, Bayle D, Dzimira S, Madej J, Rayssiguier Y, Opolski A, Mazur A. Changes in gene expression in the lungs of Mg-deficient mice are related to an inflammatory process. Magnes Res 2004; 17: 259-63.
310. Dickens BF, Weglicki WB, Li YS, Mak IT. Magnesium deficiency in vitro enhances free radical-induced intracellular oxidation and cytotoxicity in endothelial cells. FEBS Lett 1992; 311: 187-91.
311. Hans CP, Chaudhary DP, Bansal DD. Effect of magnesium supplementation on oxidative stress in alloxanic diabetic rats. Magnes Res 2003; 16: 13-9.
312. Kumar BP, Shivakumar K. Depressed antioxidant defense in rat heart in experimental magnesium deficiency. Implications for the pathogenesis of myocardial lesions. Biol Trace Elem Res 1997; 60: 139-44.
313. Rayssiguier Y, Durlach J, Gueux E, Rock E, Mazur A. Magnesium and ageing. I. Experimental data: importance of oxidative damage. Magnes Res 1993; 6: 369-78.
314. Yang Y, Wu Z, Chen Y, Qiao J, Gao M, Yuan J, Nie W, Guo Y. Magnesium deficiency enhances hydrogen peroxide production and oxidative damage in chick embryo hepatocyte in vitro. Biometals 2006; 19: 71-81.
315. Zhou Q, Olinescu RM, Kummerow FA. Influence of low magnesium concentrations in the medium on the antioxidant system in cultured human arterial endothelial cells. Magnes Res 1999; 12: 19-29.
316. Zhu Z, Kimura M, Itokawa Y. Selenium concentration and glutathione peroxidase activity in selenium and magnesium deficient rats. Biol Trace Elem Res 1993; 37: 209-17.
317. Hsu JM, Smith Jr. JC, Yunice AA, Kepford G. Impairment of ascorbic acid synthesis in liver extracts of magnesium-deficient rats. J Nutr 1983; 113: 2041-7.
318. Mak IT, Stafford R, Weglicki WB. Loss of red blood cell glutathione during Mg deficiency: prevention by vitamin E, D-propranolol, and chloroquine. Am J Physiol 1994; 267: C1366-C1370.
319. Shivakumar K, Kumar BP. Magnesium deficiency enhances oxidative stress and collagen synthesis in vivo in the aorta of rats. Int J Biochem Cell Biol 1997; 29: 1273-8.
320. Afanas'ev IB, Suslova TB, Cheremisina ZP, Abramova NE, Korkina LG. Study of antioxidant properties of metal aspartates. Analyst 1995; 120: 859-62.
321. Calviello G, Ricci P, Lauro L, Palozza P, Cittadini A. Mg deficiency induces mineral content changes and oxidative stress in rats. Biochem Mol Biol Int 1994; 32: 903-11.
322. Touyz RM, Pu Q, He G, Chen X, Yao G, Neves MF, Viel E. Effects of low dietary magnesium intake on development of hypertension in stroke-prone spontaneously hypertensive rats: role of reactive oxygen species. J Hypertens 2002; 20: 2221-32.
323. Freedman AM, Mak IT, Stafford RE, Dickens BF, Cassidy MM, Muesing RA, Weglicki WB. Erythrocytes from magnesium-deficient hamsters display an enhanced susceptibility to oxidative stress. Am J Physiol 1992; 262: C1371-C1375.
324. Weglicki WB, Bloom S, Cassidy MM, Freedman AM, Atrakchi AH, Dickens BF. Antioxidants and the cardiomyopathy of Mg-deficiency. Am J Cardiovasc Pathol 1992; 4: 210-5.
325. Gilardini L, McTernan PG, Girola A, da Silva NF, Alberti L, Kumar S, Invitti C. Adiponectin is a candidate marker of metabolic syndrome in obese children and adolescents. Atherosclerosis 2006; 189: 401-7.